CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article


Fig. 4. A, identification of TTF1 phosphorylated peptides. HeLa cells were transiently transfected with expression vectors coding for wild-type TTF1 or various serine/threonine -> alanine mutants (20) . Transfected cells were metabolically labeled for 4 h with [32P]Pi. TTF1 was immunoprecipitated with specific polyclonal antibodies, purified by PAGE, and digested with thermolysin. wt, wild-type TTF1. B, diagram illustrating the location of specific mutations and phosphopeptides. The mutants have alanine substitutions at the following sites: 1, serine 107; 2, serines 4, 12, 18, and 23 (loss of peptide b); 3, serine 255 (loss of peptides e and partly d); 4, serines 4, 12, 18, 23, 107, 255, and 328 (loss of peptides b, d, and e); 5, serines 328 and 337 (loss of peptides a, d, and f); 6, serines 4, 12, 18, 23, 107, 255, and 337 (loss of peptides b, c, d, e, and f); 7, serines 4, 12, 18, 23, 328, and 337 (loss of peptides a, b, c, d, and f). Peptide f is a fragment of peptide a. Mutant 8, serines 4, 12, 18, 23, 255, 328, and 337, is not phosphorylated in vivo (data not shown).





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation